LEXINGTON, Mass.--(BUSINESS WIRE)--Oct 21, 2023--Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company’s phase 1b study of botensilimab (BOT, multifunctional immune activator) in combination with ...
CHICAGO--(BUSINESS WIRE)--Oct 19, 2023--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that preliminary safety and efficacy data from its ongoing Phase 2 clinical trial, THIO-101, was accepted ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 19, 2023--<a ...
PRINCETON, N.J.--(BUSINESS WIRE)--Oct 19, 2023--<a ...
HENDERSON, Nev., Oct. 18, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M. Adler, U.S. Ambassador to the Kingdom of Belgium for a tour of its purpose-built research, development and manufacturing ...
SOUTHLAKE, Texas--(BUSINESS WIRE)--Oct 18, 2023--<a ...